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Abstract: Critically ill patients frequently experience stress-induced hyperglycaemia. Glycaemic control 
(GC) with insulin therapy can improve patient outcomes, but effective GC is not currently well achieved 
in most critical care units.  STAR is a model-based decision support system, utilizing the ICING model, 
for glycaemic control in intensive care. Understanding model-based parameters and assumptions within 
their clinical context is important. The ICING model uses a population constant for endogenous glucose 
production (EGP), but EGP can vary considerably in patients during extreme stress and trauma.  This 
study uses data from 145 patients on the SPRINT protocol to explore the assumptions around the EGP 
parameter and estimate minimum EGP values when the model is constrained to a minimum insulin 
sensitivity (SI) value.  The model is frequently constrained when there is no nutritional input, 
highlighting the importance of the EGP parameter for glucose flux in the model equation.  Minimum 
EGP values were calculated when SI was less than or equal to 1e-5 L/mU/min and ranged from 1.16 
mmol/min to 2.72 mmol/min, where the median value is a 12% increase from the population value of 
1.16 mmol/min.  This analysis provides a relative indication of EGP changes in patients and supports the 
use of the EGP population value as only 2.3% of hours require EGP modification. 
Keywords: Physiological model, critical care, decision support and control, clinical validation, kinetic 
modelling and control of biological systems, EGP, glycaemic control 
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1. INTRODUCTION 
Critically ill patients, regardless of diabetic status, frequently 
experience stress-induced hyperglycaemia (McCowen et al., 
2001; Mizock, 2001) that results in a positive feedback loop 
of metabolic stress and inflammation.  High and low blood 
glucose levels, hyperglycaemia and hypoglycaemia, as well 
as glycaemic variability regardless of blood glucose level, 
have all been shown to be independent risk factors for 
increased mortality in critically ill patients (Bagshaw et al., 
2009; Krinsley, 2015, 2003).  Regulating glycaemic state 
through glycaemic control (GC) in the critically ill has been 
shown to improve patient outcomes (Chase et al., 2008b; 
Krinsley, 2004; Van den Berghe et al., 2006, 2001) and 
reduce costs (Krinsley and Jones, 2006). 
Safe, effective control is required to reduced glycaemic 
variability and mitigate the risk of hypoglycaemia, in 
particular, as one episode can significantly increase risk of 
death (Penning et al., 2015). It is also critical to obtain this 
level of control for virtually all patients to ensure the 
potential benefit is obtained (Chase et al., 2010). However, 
safe, effective GC can be difficult to achieve for many 
patients due to clinical limitations and, in particular, inter- 
and intra- patient variability (Chase et al., 2011; Dickson et 
al., 2014) and may be the reason other studies have not been 
able to show benefit (Arabi et al., 2008; Griesdale et al., 
2009; Preiser et al., 2009; The NICE-SUGAR Study 
Investigators, 2009; Wiener et al., 2008). 
Physiological models such as the Intensive Control Insulin-
Nutrition-Glucose (ICING) model (Lin et al., 2011) used in 
the STAR glycaemic control protocol (Evans et al., 2012; 
Fisk et al., 2012; Stewart et al., 2016) have demonstrated 
repeatable, replicable, safe and effective GC. Such model-
based methods can directly account for and use the inter- and 
intra- patient variability to guide control (Lin et al., 2006). 
The ICING model captures basic metabolic physiology well, 
and has been used in the design and implementation of 
glycaemic control protocols such as STAR  and SPRINT, to 
provide effective GC for virtually all patients (Chase et al., 
2010, 2008a; Stewart et al., 2016; Uyttendaele et al., 2017). 
However, there are limitations to the models, particularly the 
assumptions used around dynamics which are not easily 
measured at the bedside or are difficult to separate from other 
related dynamics. Endogenous glucose production (EGP) is 
one such important dynamic, particularly in the critically ill. 
EGP is very difficult and extremely invasive to measure 
directly, requiring arterial-venous balance or tracer methods 
(Rizza et al., 2016) for durations longer than 2.5 hours (Tigas 
et al., 2002), thus making its measurement both highly 
intensive and time consuming. EGP can be highly variable 
(Black et al., 1982; Chiolero et al., 2000; Shaw and Wolfe, 
1989; Tappy et al., 1997) and elevated due to stress-response 
(McCowen et al., 2001). Significant inter-patient variability 
in EGP measurements may reflect physiological responses or 
it may also reflect issues in clinical assessment of EGP.   
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Different attempts have been made to model EGP in critically 
ill patients, including as a function of plasma insulin 
(Hovorka et al., 2008), BG and insulin (Pielmeier et al., 
2010), and BG, insulin, and glucagon (Wendt et al., 2017).  
Many of these models fail to capture the complexity of EGP 
stimulus and suppression in stress hyperglycaemia and/or 
rely on additional blood measures, assays and/or procedures 
that are not available or clinically feasible to perform at the 
bedside. Hence, there is no accepted, proven, or ready way to 
model or assume a value of EGP in this cohort. 
Previous attempts at varying EGP dynamics resulted in 
unstable BG control dynamics (Dickson et al., 2013; Pretty, 
2012) using the ICING model. Currently, EGP is a 
population constant and error in this value is adsorbed as an 
offset on patient-specific, identified insulin sensitivity (SI). 
The stochastic modelling approach captures this variability 
and helps guide care (Le Compte et al., 2011; Lin et al., 
2008).  In extreme cases, when physiological EGP is much 
higher than the model population constant, negative SI values 
can be identified that are not physiologically possible, and 
this can skew care. 
This study uses the validated ICING model (Lin et al., 2011; 
Stewart et al., 2016) to assess model parameter values during 
low, identified SI events in critically ill patients. The aim is 
to quantify the frequency of these events and quantify a lower 
bound, by enhanced or higher EGP value during the events. 
The results can then be used to determine whether the impact 
influences care choices. 
2. METHODS 
2.1 Patient Demographics 
Study data comprises 145 patients on SPRINT GC (Chase et 
al., 2008a; Lonergan et al., 2006) in Christchurch Hospital 
ICU from June 2011 to May 2015.  Patients were on the 
protocol for a minimum of 24 hours and started GC within 12 
hours of ICU admission to ensure timing was the same.  The 
average patient length of ICU stay was 113 hours, with 83 
hours on SPRINT. Up to the first 72 hours on SPRINT was 
analysed for each patient, making 9,304 hours of GC in the 
data set. Demographic data can be found in (Uyttendaele et 
al., 2017). 
2.2 Model and SI 
The metabolic system dynamics of the ICING (Intensive 
Control Insulin Nutrition Glucose) physiological model are 







Where G(t) is blood glucose concentration (mmol/L), I(t) is 
plasma insulin concentration (mU/L), Q(t) is interstitial 
insulin concentration (mU/L), P(t) is plasma glucose from 
dextrose intake (mmol/min) and SI is insulin sensitivity 
(L/mU/min).  EGP is endogenous glucose production and has 
a constant population value of 1.16 mmol/min (Lin et al., 
2011), per values in (Chambrier et al., 2000).  Other rates and 
constants can be found in (Stewart et al., 2018). A detailed 
model description can be found in (Lin et al., 2011). 
 
 
Figure 1. Schematic representation of the glucose-insulin 
model showing endogenous and exogenous contributions. 
CNS Central nervous system, EGP Endogenous glucose 
production, PN Parenteral nutrition, SI Insulin sensitivity, u 
insulin, d glucose transport rate, pG non-insulin mediated 
glucose removal, n insulin diffusion/degradation rates. 
Patient metabolic ability for insulin mediated glucose uptake 
is captured using hour-to-hour relative changes in a model-
based insulin sensitivity (SI) value.  Hourly insulin sensitivity 
(SI) values based on clinical inputs of measured blood 
glucose, and insulin and glucose administration are identified 
using an integral based fitting method (Docherty et al., 2012, 
2011). 
2.3 Calculation of lower bound enhanced EGP 
An SI value of 1e-5 L/mU/min is taken to be reflective of the 
likely lower limit of physiological SI, and is around 100x 
lower than SI in individuals with diabetes (Lotz et al., 2010; 
McAuley et al., 2011). During periods when SI is identified 
at or below SI = 1e-5 L/mU/min, the model SI value can be 
constrained to 1e-5 L/mU/min, and a new augmented, but 
lower bound EGP value calculated directly. This calculation 
of EGP ensures model fit to clinical BG measures where non-
insulin mediated glucose uptake is higher than the modelled 
glucose sources in the G compartment of Equation 1. This 
calculated EGP value is a minimum or lower bound estimate 
of what the elevated EGP value at this time could be. A 
higher EGP value would result in SI >1e-5 L/mU/min, but is 
not identifiable without significant extra data and/or 
procedures. This lower bound enhanced EGP during hours 
with constrained SI is calculated: 
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Where GE is end blood glucose concentration (mmol/L) and 
GS is starting blood glucose concentration (mmol/L), and all 
other parameters are defined previously. Integrals are 
evaluated over the identified 1 hour period where SI is 
constrained at 1e-5 L/mU/min. 
Identified SI values that are negative indicate that the EGP 
value may need to be augmented. Constrained values are 
clear limit states and resulting BG error would be due to error 
in the assumed EGP population value as shown in Figure 2.  
The approach separates clear cases where the EGP value is in 
error, making this value identifiable. It is thus a minimal 
estimate of enhanced EGP level and incidence. 
 
Figure 2.  During stress response, EGP can be significantly 
elevated resulting in blood glucose (BG) model predictions 
(blue line) not matching actual BG level (red crosses). 
2.4 Analyses 
Time periods when EGP is significantly enhanced over 
assumed model values were identified by evaluating when SI 
was constrained to 1e-5 L/mU/min.  Time and length of 
events are tabulated and single 1-hour events are excluded in 
further analysis as they were found to be primarily due to 
data entry or sensor errors.  All events lasting 2 or more 
consecutive hours are further evaluated. 
The rate of EGP can be significantly increased over the 
constant population value due to stress response, particularly 
in the most critically ill ICU patients, and this increase can be 
a large contributor to glucose flux. EGP values were 
calculated for those hours when the identified SI values were 
less than or equal to 1e-5 L/mU/min.  The range, time, and 
frequency of EGP values were evaluated and compared to 
clinical observations and expectations. 
3. RESULTS 
3.1 Insulin Sensitivity (SI) and constrained events 
A total of 214 low SI hours were analysed.  The cumulative 
distribution function (CDF) of the calculated SI values, 
excluding 1 hour events, is shown in Figure 3 with 2.3% of 
values below or equal to the SI = 1e-5 L/mU/min minimum 
level.  Though relatively scarce by hour (2.3% of 9,304 total 
hours), 45.5% of patients have at least 1 event of constrained 
SI lasting 2 or more hours.  
3.2 Patient and care states during constrained events 
Table 1 shows the percentage of constrained events occurring 
during particular parameter states. Less than one-third of 
events occurred when no insulin was being administered, but 
more than 80% of constrained SI events occurred when 
nutrition was not being administered in the current hour. In 
particular, with no (or low) nutritional intake, the model 
relies excessively on the accuracy of the assumed EGP 
population parameter’s to capture incoming glucose flux 
(Chase et al., 2009).  It thus supports the choice of modifying 
the EGP parameter value in these cases and this analysis. 
 
 
Figure 3. Cumulative distribution function of model-
identified SI values.  Note that the x-axis is a log scale. 
 
Table 1. Input states when SI is less than or equal to 1e-5 
L/mU/min. 
Input condition % constrained SI hours 
No insulin in constrained hour 28.7% 
No nutrition in constrained hour 82.6% 
No insulin or nutrition in 
constrained hour 
24.6% 
No nutrition in previous hour 79.5% 
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Figure 4. Minimum EGP values calculated using SI = 1e-5 
L/mU/min during hours when SI is constrained.  The bar 
chart shows hourly incidence of minimum EGP values (left 
y-axis) and the solid line is the cumulative distribution (right 
y-axis) of minimum EGP values for all constrained hours. 
 
3.3 Calculated Minimum EGP Values 
During constrained events, when SI was less than or equal to 
1e-5 L/mU/min, a minimum EGP value was calculated from 
Equation 4 using the constrained SI value of 1e-5 L/mU/min. 
Minimum EGP values ranged from 1.16 to 2.72 mmol/min, 
with 50% of the values being above 1.31 mmol/min.  The 
median value is a 12% increase from the assumed population 
value of 1.16 mmol/min used in the model.  Five percent of 
values are greater than 1.88 mmol/min, representing a 62% 
increase from the assumed population value. 
4. DISCUSSION 
This analysis used a model-based approach to evaluate an 
increased lower bound enhanced EGP value in critically ill 
patients based on incidence, the time dependent nature and 
extent of lower bound, constrained SI values, and associated 
likely high EGP. This approach allows this lower bound EGP 
value to be directly identified by constraining SI to non-
negative values.  The range of SI values shown in Figure 3 
are 100x lower than a typical type 2 diabetic individual (Lotz 
et al., 2010; McAuley et al., 2011), which also captures and 
clearly shows the significant stress response insulin resistance 
seen in critically ill patients. 
EGP affects the glucose flux in Equation 1, but is difficult to 
measure directly (Rizza et al., 2016). It also increases 
significantly and variably during the stress response (Dickson 
et al., 2013; McCowen et al., 2001; Watters et al., 1997).  It 
thus, in part, affects the increased variability of insulin 
sensitivity in the initial stage of critical illness (Pretty et al., 
2012).  EGP can be significantly elevated early in the patient 
stay as part of stress response and these patients may require 
adjustment of the EGP value used, although the constant 
value of EGP=1.16 mmol/min chosen (Chambrier et al., 
2000; Lin et al., 2011) is suitable for the vast majority of 
patients at all time points. 
The range of 1.16 to 2.72 mmol/min found in this study is 
within other published ranges of trauma patients (Chiolero et 
al., 2000; Tappy et al., 1997; Wolfe et al., 1979). The 
reported range of enhanced lower bound EGP values reflects 
a minimum estimate of elevated EGP production in these 
incidences as it is calculated based as a lower bound, 
constrained SI value. Thus, the incidence and level of 
augmented EGP reported here are lower bounds and may be 
higher, but the conditions used here ensure identifiability of 
the problem so the results are robust. 
Parameter trade-off in the model can affect the incidence of 
low SI, and was considered in this analysis. The most likely 
parameter in this case is EGP because of the known 
physiological response, and because 80% of low SI 
occurrences happen when there is no exogenous nutrition 
being administered, as shown in Table 1.  The only other 
source of glucose to keep BG elevated is the much greater 
rate of appearance from exogenous sources, which Table 1 
shows are often not present in these instances, clearly 
highlighting the role of EGP physiologically and in the 
model. In this case, the results thus match clinical 
expectations and within the model, the error is amplified in 
the case of low to no exogenous nutritional input and it leaves 
only the EGP value as a cause of error. 
When there is a difference between the actual physiological 
EGP value and the model assumed term, the error is usually 
minimized because the patient is fed at much higher rates 
than the EGP term, thus minimizing EGP contribution 
overall. This implies that patients with low, but unconstrained 
SI could have higher EGP and higher peripheral SI, but are 
not detected. Currently, there is no known way to identify 
these patients at the bedside (Docherty et al., 2011), making 
implementation of variable EGP based on bedside measures 
less practicable at this time, especially because it can vary 
significantly due to stress response and over the wide range 
found here. 
The model used in this analysis has been proven both 
clinically and analytically (Chase et al., 2019; Lin et al., 
2011; Stewart et al., 2016) and used in a variety of contexts. 
The data set comprised a mixed cohort, single centre 
population, and as patients are variable, a larger cohort study 
in multiple centres would offer more insight into EGP 
variation. 
5. CONCLUSIONS 
Model-based insulin sensitivity was constrained to a 
physiologically realistic lower limit in 2.3% of patient hours 
on model-based glycaemic control. This constrained SI most 
likely represents model error in the EGP parameter in these 
cases, as most of the constraints occurred around low or no 
nutritional input periods. It also reflects the stress response, 
as the majority of constrained SI values occurred in the first 
12 hours of insulin therapy. Minimum EGP values calculated 
in the case of constrained SI varied from 1.16 to 2.72 
mmol/min, which are within reported ranges for this cohort 
and thus physiologically realistic, further validating the 
model and analysis. Overall, the current population value of 
1.16 mmol/min used in the model is justified given less than 
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incidences as it is calculated based as a lower bound, 
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augmented EGP reported here are lower bounds and may be 
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the problem so the results are robust. 
Parameter trade-off in the model can affect the incidence of 
low SI, and was considered in this analysis. The most likely 
parameter in this case is EGP because of the known 
physiological response, and because 80% of low SI 
occurrences happen when there is no exogenous nutrition 
being administered, as shown in Table 1.  The only other 
source of glucose to keep BG elevated is the much greater 
rate of appearance from exogenous sources, which Table 1 
shows are often not present in these instances, clearly 
highlighting the role of EGP physiologically and in the 
model. In this case, the results thus match clinical 
expectations and within the model, the error is amplified in 
the case of low to no exogenous nutritional input and it leaves 
only the EGP value as a cause of error. 
When there is a difference between the actual physiological 
EGP value and the model assumed term, the error is usually 
minimized because the patient is fed at much higher rates 
than the EGP term, thus minimizing EGP contribution 
overall. This implies that patients with low, but unconstrained 
SI could have higher EGP and higher peripheral SI, but are 
not detected. Currently, there is no known way to identify 
these patients at the bedside (Docherty et al., 2011), making 
implementation of variable EGP based on bedside measures 
less practicable at this time, especially because it can vary 
significantly due to stress response and over the wide range 
found here. 
The model used in this analysis has been proven both 
clinically and analytically (Chase et al., 2019; Lin et al., 
2011; Stewart et al., 2016) and used in a variety of contexts. 
The data set comprised a mixed cohort, single centre 
population, and as patients are variable, a larger cohort study 
in multiple centres would offer more insight into EGP 
variation. 
5. CONCLUSIONS 
Model-based insulin sensitivity was constrained to a 
physiologically realistic lower limit in 2.3% of patient hours 
on model-based glycaemic control. This constrained SI most 
likely represents model error in the EGP parameter in these 
cases, as most of the constraints occurred around low or no 
nutritional input periods. It also reflects the stress response, 
as the majority of constrained SI values occurred in the first 
12 hours of insulin therapy. Minimum EGP values calculated 
in the case of constrained SI varied from 1.16 to 2.72 
mmol/min, which are within reported ranges for this cohort 
and thus physiologically realistic, further validating the 
model and analysis. Overall, the current population value of 
1.16 mmol/min used in the model is justified given less than 
 
 
     
 
2.5% of hours are constrained, representing a small subset of 
patients and hours with physiology that is not well-captured 
in the current model. 
REFERENCES 
Arabi, Y.M., Dabbagh, O.C., Tamim, H.M., Al-Shimemeri, 
A.A., Memish, Z.A., Haddad, S.H., Syed, S.J., Giridhar, 
H.R., Rishu, A.H., Al-Daker, M.O., Kahoul, S.H., Britts, 
R.J., Sakkijha, M.H., 2008. Intensive versus conventional 
insulin therapy: A randomized controlled trial in medical 
and surgical critically ill patients. Crit. Care Med. 36, 
3190–3197. 
Bagshaw, S.M., Bellomo, R., Jacka, M.J., Egi, M., Hart, 
G.K., George, C., 2009. The impact of early 
hypoglycemia and blood glucose variability on outcome 
in critical illness. Crit. Care 13, 1–10. 
Black, P.R., Brooks, D.C., Bessey, P.Q., Wolfe, R.R., 
Wilmore, D.W., 1982. Mechanisms of insulin resistance 
following injury. Ann. Surg. 196, 420–435. 
Chambrier, C., Laville, M., Rhzioual Berrada, K., Odeon, M., 
Bouletreau, P., Beylot, M., 2000. Insulin sensitivity of 
glucose and fat metabolism in severe sepsis. Clin. Sci. 99, 
321–328. 
Chase, J.G., Andreassen, S., Pielmeier, U., Hann, C.E., 
McAuley, K.A., Mann, J.I., 2009. A glucose-insulin 
pharmacodynamic surface modeling validation and 
comparison of metabolic system models. Biomed. Signal 
Process. Control 4, 355–363. 
Chase, J.G., Benyo, B., Desaive, T., 2019. Glycemic control 
in the intensive care unit: A control systems perspective. 
Annu. Rev. Control. 
Chase, J.G., Le Compte, A.J., Suhaimi, F., Shaw, G.M., 
Lynn, A., Lin, J., Pretty, C.G., Razak, N., Parente, J.D., 
Hann, C.E., Preiser, J.C., Desaive, T., 2011. Tight 
glycemic control in critical care - The leading role of 
insulin sensitivity and patient variability: A review and 
model-based analysis. Comput. Methods Programs 
Biomed. 102, 156–171. 
Chase, J.G., Pretty, C.G., Pfeifer, L., Shaw, G.M., Preiser, 
J.C., Le Compte, A.J., Lin, J., Hewett, D., Moorhead, 
K.T., Desaive, T., 2010. Organ failure and tight glycemic 
control in the SPRINT study. Crit. Care 14. 
Chase, J.G., Shaw, G., Le Compte, A., Lonergan, T., 
Willacy, M., Wong, X.-W., Lin, J., Lotz, T., Lee, D., 
Hann, C., 2008a. Implementation and evaluation of the 
SPRINT protocol for tight glycaemic control in critically 
ill patients: a clinical practice change. Crit. Care 12, R49. 
Chase, J.G., Shaw, G., Le Compte, A., Lonergan, T., 
Willacy, M., Wong, X.W., Lin, J., Lotz, T., Lee, D., 
Hann, C., 2008b. Implementation and evaluation of the 
SPRINT protocol for tight glycaemic control in critically 
ill patients: A clinical practice change. Crit. Care 12, 1–
15. 
Chiolero, R.L., Revelly, J.-P., Leverve, X., Gersbach, P., 
Cayeux, M.-C., Berger, M.M., Tappy, L., 2000. Effects of 
cardiogenic shock on lactate and glucose metabolism after 
heart surgery. Crit Care Med 28. 
Dickson, J.L., Gunn, C.A., Chase, J.G., 2014. Human are 
Horribly Variable 1. 
Dickson, J.L., Hewett, J.N., Gunn, C.A., Lynn, A., Shaw, 
G.M., Chase, J.G., 2013. On the problem of patient-
specific endogenous glucose production in neonates on 
stochastic targeted glycemic control. J. Diabetes Sci. 
Technol. 7, 913–927. 
Docherty, P.D., Chase, J.G., David, T., 2012. 
Characterisation of the iterative integral parameter 
identification method. Med. Biol. Eng. Comput. 50, 127–
134. 
Docherty, P.D., Chase, J.G., Lotz, T.F., Desaive, T., 2011. A 
graphical method for practical and informative 
identifiability analyses of physiological models: A case 
study of insulin kinetics and sensitivity. Biomed. Eng. 
Online 10, 39. 
Evans, A., Le Compte, A., Tan, C.S., Ward, L., Steel, J., 
Pretty, C.G., Penning, S., Suhaimi, F., Shaw, G.M., 
Desaive, T., Chase, J.G., 2012. Stochastic targeted 
(STAR) glycemic control: Design, safety, and 
performance. J. Diabetes Sci. Technol. 6, 102–115. 
Fisk, L.M., Le Compte, A.J., Shaw, G.M., Penning, S., 
Desaive, T., Chase, J.G., 2012. STAR development and 
protocol comparison. IEEE Trans. Biomed. Eng. 59, 
3357–3364. 
Griesdale, D.E.G., De Souza Rd, R.J., Van Dam, R.M., 
Heyland, D.K., Cook, D.J., Malhotra, A., Dhaliwal, R., 
Henderson, W.R., Chittock, D.R., Finfer, S., Talmor, D., 
2009. Intensive insulin therapy and mortality among 
critically ill patients: A meta-analysis including NICE-
SUGAR study data. Cmaj 180, 821–827. 
Hovorka, R., Chassin, L.J., Ellmerer, M., Plank, J., Wilinska, 
M.E., 2008. A simulation model of glucose regulation in 
the critically ill. Physiol. Meas. 29, 959–978. 
Krinsley, J.S., 2003. Association between Hyperglycemia 
and Increased Hospital Mortality in a Heterogeneous 
Population of Critically Ill Patients. Mayo Clin. Proc. 78, 
1471–1478. 
Krinsley, J.S., 2004. Effect of an intensive glucose 
management protocol on the mortality of critically Ill 
adult patients. Mayo Clin. Proc. 79, 992–1000. 
Krinsley, J.S., 2015. Glycemic control in the critically ill: 
What have we learned since NICE-SUGAR? Hosp. Pract. 
(1995) 43, 191–197. 
Krinsley, J.S., Jones, R.L., 2006. Cost analysis of intensive 
glycemic control in critically ill adult patients. Chest 129, 
644–650. 
Le Compte, A.J., Chase, J.G., Lynn, A., Hann, C.E., Shaw, 
G.M., Lin, J., 2011. Development of blood glucose 
control for extremely premature infants. Comput. 
Methods Programs Biomed. 102, 181–191. 
Lin, J., Lee, D., Chase, J.G., Shaw, G.M., Hann, C.E., Lotz, 
T., Wong, J., 2006. Stochastic modelling of insulin 
sensitivity variability in critical care. Biomed. Signal 
Process. Control 1, 229–242. 
Lin, J., Lee, D., Chase, J.G., Shaw, G.M., Le Compte, A., 
Lotz, T., Wong, J., Lonergan, T., Hann, C.E., 2008. 
Stochastic modelling of insulin sensitivity and adaptive 
glycemic control for critical care. Comput. Methods 
Programs Biomed. 89, 141–152. 
Lin, J., Razak, N.N., Pretty, C.G., Le Compte, A., Docherty, 
P., Parente, J.D., Shaw, G.M., Hann, C.E., Geoffrey 
Chase, J., 2011. A physiological Intensive Control 
16160 Jennifer J. Ormsbee  et al. / IFAC PapersOnLine 53-2 (2020) 16155–16160
 
 
     
 
Insulin-Nutrition-Glucose (ICING) model validated in 
critically ill patients. Comput. Methods Programs 
Biomed. 102, 192–205. 
Lonergan, T., Le Compte, A., Willacy, M., Chase, J.G., 
Shaw, G.M., Hann, C.E., Lotz, T., Lin, J., Wong, X.W., 
2006. A pilot study of the SPRINT protocol for tight 
glycemic control in critically ill patients. Diabetes 
Technol. Ther. 8, 449–462. 
Lotz, T.F., Chase, J.G., McAuley, K.A., Shaw, G.M., 
Docherty, P.D., Berkeley, J.E., Williams, S.M., Hann, 
C.E., Mann, J.I., 2010. Design and clinical pilot testing of 
the model-based Dynamic Insulin Sensitivity and 
Secretion Test (DISST). J. Diabetes Sci. Technol. 4, 
1408–1423. 
McAuley, K.A., Berkeley, J.E., Docherty, P.D., Lotz, T.F., 
Te Morenga, L.A., Shaw, G.M., Williams, S.M., Chase, 
J.G., Mann, J.I., 2011. The dynamic insulin sensitivity 
and secretion test-a novel measure of insulin sensitivity. 
Metabolism. 60, 1748–1756. 
McCowen, K.C., Malhotra, A., Bistrian, B.R., 2001. Stress-
Induced hyperglycemia. Crit. Care Clin. 17, 107–124. 
Mizock, B.A., 2001. Alterations in fuel metabolism in critical 
illness: Hyperglycaemia. Best Pract. Res. Clin. 
Endocrinol. Metab. 15, 533–551. 
Penning, S., Pretty, C., Preiser, J.C., Shaw, G.M., Desaive, 
T., Chase, J.G., 2015. Glucose control positively 
influences patient outcome: A retrospective study. J. Crit. 
Care 30, 455–459. 
Pielmeier, U., Andreassen, S., Nielsen, B.S., Chase, J.G., 
Haure, P., 2010. A simulation model of insulin saturation 
and glucose balance for glycemic control in ICU patients. 
Comput. Methods Programs Biomed. 97, 211–222. 
Preiser, J.C., Devos, P., Ruiz-Santana, S., Mélot, C., Annane, 
D., Groeneveld, J., Iapichino, G., Leverve, X., Nitenberg, 
G., Singer, P., Wernerman, J., Joannidis, M., Stecher, A., 
Chioléro, R., 2009. A prospective randomised multi-
centre controlled trial on tight glucose control by 
intensive insulin therapy in adult intensive care units: The 
Glucontrol study. Intensive Care Med. 35, 1738–1748. 
Pretty, C., 2012. Analysis , classification and management of 
insulin sensitivity variability in a glucose-insulin system 
model for critical illness. Thesis. 
Pretty, C.G., Le Compte, A.J., Geoffrey Chase, J., Shaw, 
G.M., Preiser, J.C., Penning, S., CDesaive, T., 2012. 
Variability of insulin sensitivity during the first 4 days of 
critical illness: Implications for tight glycemic control. 
Ann. Intensive Care 2, 1–19. 
Rizza, R.A., Toffolo, G., Cobelli, C., 2016. Accurate 
measurement of postprandial glucose turnover: Why is it 
difficult and how can it be done (relatively) simply? 
Diabetes. 
Shaw, J.H.F., Wolfe, R.R., 1989. An integrated analysis of 
glucose, fat, and protein metabolism in severely 
traumatized patients. Studies in the basal state and the 
response to total parenteral nutrition. Ann. Surg. 209, 63–
72. 
Stewart, K.W., Pretty, C.G., Shaw, G.M., Chase, J.G., 2018. 
Creating smooth SI. B-spline basis function 
representations of insulin sensitivity. Biomed. Signal 
Process. Control 44, 270–278. 
Stewart, K.W., Pretty, C.G., Tomlinson, H., Thomas, F.L., 
Homlok, J., Noémi, S.N., Illyés, A., Shaw, G.M., Benyó, 
B., Chase, J.G., 2016. Safety, efficacy and clinical 
generalization of the STAR protocol: a retrospective 
analysis. Ann. Intensive Care 6. 
Tappy, L., Tounian, P., Paquot, N., 1997. Autoregulation of 
endogenous glucose production in man. Biochem. Soc. 
Trans. 25, 11–13. 
The NICE-SUGAR Study Investigators, 2009. Intensive 
versus Conventional Glucose Control in Critically Ill 
Patients. N. Engl. J. Med. 360, 609–619. 
Tigas, S.K., Sunehag, A.L., Haymond, M.W., 2002. Impact 
of duration of infusion and choice of isotope label on 
isotope recycling in glucose homeostasis. Diabetes 51, 
3170–3175. 
Uyttendaele, V., Dickson, J.L., Shaw, G.M., Desaive, T., 
Chase, J.G., 2017. Untangling glycaemia and mortality in 
critical care. Crit. Care. 
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, 
W., Wouters, P.J., Milants, I., Van Wijngaerden, E., 
Bobbaers, H., Bouillon, R., 2006. Intensive Insulin 
Therapy in the Medical ICU 354. 
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., 
Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, 
P., Lauwers, P., Bouill, 2001. Intensive Insulin Therapy in 
Critically Ill Patients. N. Engl. J. Med. 345, 1359–1367. 
Watters, J.M., Norris, S.B., Kirkpatrick, S.M., 1997. 
Endogenous glucose production following injury 
increases with age. J. Clin. Endocrinol. Metab. 82, 3005–
3010. 
Wendt, S.L., Ranjan, A., Møller, J.K., Schmidt, S., Knudsen, 
C.B., Holst, J.J., Madsbad, S., Madsen, H., Nørgaard, K., 
Jørgensen, J.B., 2017. Cross-Validation of a Glucose-
Insulin-Glucagon Pharmacodynamics Model for 
Simulation Using Data From Patients With Type 1 
Diabetes. J. Diabetes Sci. Technol. 11, 1101–1111. 
Wiener, R.S., Wiener, D.C., Larson, R.J., 2008. Benefits and 
Risks of Tight Glucose Control in Critically Ill Adults: A 
Meta-analysis. Jama 300, 933–944. 
Wolfe, R.R., Durkot, M.J., Allsop, J.R., Burke, J.F., 1979. 
Glucose metabolism in severely burned patients. 
Metabolism 28, 1031–1039. 
 
